Aileron Therapeutics Inc.
| NASDAQ: ALRN | Healthcare / Biotechnology / USA |
| 2.12 | +0.1999 | +10.41% | Vol 108.04K | 1Y Perf -30.68% |
| Nov 30th, 2023 16:00 DELAYED |
| BID | 2.04 | ASK | 2.13 | ||
| Open | 1.95 | Previous Close | 1.92 | ||
| Pre-Market | - | After-Market | - | ||
| - -% | - - |
| Target Price | 40.00 | Analyst Rating | Hold 3.00 | |
| Potential % | 1.79K | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★★+ — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 48.47 | Earnings Rating | Neutral | |
| Market Cap | 9.63M | Earnings Date | 7th Nov 2023 | |
| Alpha | -0.03 | Standard Deviation | 0.37 | |
| Beta | 2.14 |
Today's Price Range 1.932.15 | 52W Range 1.013.30 | 5 Year PE Ratio Range -4.60-0.9000 |
Summary:
Buy
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | 14.59% | ||
| 1 Month | 59.47% | ||
| 3 Months | 27.71% | ||
| 6 Months | 44.22% | ||
| 1 Year | -30.68% | ||
| 3 Years | 98.13% | ||
| 5 Years | -2.30% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -140.56 | |||
ROE last 12 Months | -90.82 | |||
ROA (5Y Avg) | -29.07 | |||
ROA last 12 Months | -80.35 | |||
ROC (5Y Avg) | -72.94 | |||
ROC last 12 Months | -80.97 | |||
Return on invested Capital Q | -25.17 | |||
Return on invested Capital Y | -14.41 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | - |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -0.40 | ||||
| 0.52 | ||||
| - | ||||
| - | ||||
| -0.60 | ||||
| -5.89 | ||||
| 0.52 | ||||
| 5.00 | ||||
| -13 512 100.00 | ||||
| Forward PE | -1.32 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 5.60 | ||||
| 6.00 | ||||
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| Leverage Ratio | 1.20 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2023 | - | -0.40 | - |
| Q02 2023 | - | -0.39 | - |
| Q01 2023 | - | -0.82 | - |
| Q03 2022 | -1.60 | -1.40 | 12.50 |
| Q02 2022 | -1.80 | -1.80 | 0.00 |
| Q01 2022 | -1.60 | -1.80 | -12.50 |
| Q04 2021 | - | -1.60 | - |
| Q03 2021 | -1.40 | -1.40 | 0.00 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 12/2022 QR | -1.40 | 6.67 | Positive |
| 3/2023 QR | -1.20 | 0.00 | - |
| 12/2023 FY | -1.40 | 0.00 | - |
| 12/2023 FY | -1.40 | 63.16 | Positive |
| Next Report Date | - |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 108.04K |
| Shares Outstanding | 4.54K |
| Shares Float | 3.37M |
| Trades Count | 368 |
| Dollar Volume | 219.56K |
| Avg. Volume | 63.92K |
| Avg. Weekly Volume | 21.93K |
| Avg. Monthly Volume | 122.36K |
| Avg. Quarterly Volume | 47.48K |
Aileron Therapeutics Inc. (NASDAQ: ALRN) stock closed at 2.12 per share at the end of the most recent trading day (a 10.41% change compared to the prior day closing price) with a volume of 108.04K shares and market capitalization of 9.63M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 13 people. Aileron Therapeutics Inc. CEO is Manuel C. Alves Aivado.
The one-year performance of Aileron Therapeutics Inc. stock is -30.68%, while year-to-date (YTD) performance is -10.55%. ALRN stock has a five-year performance of -2.3%. Its 52-week range is between 1.01 and 3.3, which gives ALRN stock a 52-week price range ratio of 48.47%
Aileron Therapeutics Inc. currently has a PE ratio of -0.40, a price-to-book (PB) ratio of 0.52, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -80.35%, a ROC of -80.97% and a ROE of -90.82%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Aileron Therapeutics Inc., there were 1 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Aileron Therapeutics Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Aileron Therapeutics Inc. is Hold (3), with a target price of $40, which is +1 786.79% compared to the current price. The earnings rating for Aileron Therapeutics Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Aileron Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Aileron Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 26.89, ATR14 : 0.15, CCI20 : 127.25, Chaikin Money Flow : 0.43, MACD : 0.16, Money Flow Index : 96.82, ROC : 19.10, RSI : 70.46, STOCH (14,3) : 95.95, STOCH RSI : 1.00, UO : 72.29, Williams %R : -4.05), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Aileron Therapeutics Inc. in the last 12-months were:
Aileron Therapeutics Inc.
Aileron Therapeutics Inc a clinical-stage biopharmaceutical company. It is focused on developing and commercializing a novel class of therapeutics called stapled peptides. The company's lead product candidate, ALRN-6924, targets the tumor suppressor p53 for the treatment of a wide variety of cancers.
CEO: Manuel C. Alves Aivado
Telephone: +1 617 995-0900
Address: 490 Arsenal Way, Watertown 02472, MA, US
Number of employees: 13
